rp6530
Small moleculeexperimental
Clinical trial activity
3 trials · 6 clinical orgs · 0 marketing orgs
Phase 1
3
Phase 2
0
Phase 3
0
Phase 4
0
Earliest trial started Nov 1, 2013 (NCT02017613)
Timeline
2010s
- Jan 1, 2013
Earliest Phase 1 Sponsor(trial)
Indications
Mechanism of action
Chemistry & pharmacology
- Chirality
- Single Stereoisomer
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL3545141 ↗
Also known as
- rp6530
- rp6530
- rp-6530
- rp-6530
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT02690727 | Phase 1 | Feb 1, 2016 | Algorithme Pharma Inc, Rhizen Pharmaceuticals SA |
| NCT02567656 | Phase 1 | Sep 1, 2015 | Rhizen Pharmaceuticals SA, University of Texas at Houston |
| NCT02017613 | Phase 1 | Nov 1, 2013 | Humanitas University, Rhizen Pharmaceuticals SA, University of Paris, Vita-Salute University of Milano. Italy |
Showing 3 of 3 trials
Page 1 / 1
Organizations
Research & Development (6)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Rhizen Pharmaceuticals SA | For profit | 3 | 3 | 1 | 2013 |
| Algorithme Pharma Inc | For profit | 1 | 0 | 1 | 2016 |
| Humanitas University | Academic/Hospital | 1 | 0 | 1 | 2013 |
| University of Paris | Academic/Hospital | 1 | 0 | 1 | 2013 |
| University of Texas at Houston | Academic/Hospital | 1 | 0 | 1 | 2015 |
| Vita-Salute University of Milano. Italy | Academic/Hospital | 1 | 0 | 1 | 2013 |
6 organizations
Page 1 / 1